Drug class
Short-acting inhaled anticholinergic agents, also referred to as short-acting muscarinic antagonists (SAMAs), are a therapeutic class of bronchodilators administered by inhalation to relieve acute airflow obstruction. Read more about Anticholinergic Agents Short-Acting (Inhaled)
22 drugs in this class 13 manufacturers
Short-acting inhaled anticholinergic agents, also referred to as short-acting muscarinic antagonists (SAMAs), are a therapeutic class of bronchodilators administered by inhalation to relieve acute airflow obstruction.
They function by competitively antagonizing muscarinic acetylcholine receptors on bronchial smooth muscle, preventing acetylcholine-mediated vagal bronchoconstriction and excessive mucus secretion.
Clinically typified by ipratropium bromide, these agents provide rapid-onset airway relaxation and are primarily utilized for the maintenance and acute management of chronic obstructive pulmonary disease (COPD) as well as adjunctive therapy in moderate-to-severe acute asthma exacerbations.
Short-acting inhaled anticholinergic agents, also referred to as short-acting muscarinic antagonists (SAMAs), are a therapeutic class of bronchodilators administered by inhalation to relieve acute airflow obstruction They function by competitively antagonizing muscarinic acetylcholine receptors on bronchial smooth muscle, preventing acetylcholine-mediated vagal bronchoconstriction and excessive mucus secretion Clinically typified by ipratropium bromide, these agents provide rapid-onset airway re...
Short-acting inhaled anticholinergic agents, also referred to as short-acting muscarinic antagonists (SAMAs), are a therapeutic class of bronchodilators administered by inhalation to relieve acute airflow obstruction
Short-acting inhaled anticholinergic agents, also referred to as short-acting muscarinic antagonists (SAMAs), are a therapeutic class of bronchodilators administered by inhalation to relieve acute airflow obstruction Clinically typified by ipratropium bromide, these agents provide rapid-onset airway relaxation and are primarily utilized for the maintenance and acute management of chronic obstructive pulmonary disease (COPD) as well as adjunctive therapy in moderate-to-severe acute asthma exacerb...
They function by competitively antagonizing muscarinic acetylcholine receptors on bronchial smooth muscle, preventing acetylcholine-mediated vagal bronchoconstriction and excessive mucus secretion Clinically typified by ipratropium bromide, these agents provide rapid-onset airway relaxation and are primarily utilized for the maintenance and acute management of chronic obstructive pulmonary disease (COPD) as well as adjunctive therapy in moderate-to-severe acute asthma exacerbations
They function by competitively antagonizing muscarinic acetylcholine receptors on bronchial smooth muscle, preventing acetylcholine-mediated vagal bronchoconstriction and excessive mucus secretion
Clinically typified by ipratropium bromide, these agents provide rapid-onset airway relaxation and are primarily utilized for the maintenance and acute management of chronic obstructive pulmonary disease (COPD) as well as adjunctive therapy in moderate-to-severe acute asthma exacerbations
Following a drug class requires a free Physicians Office Resource account.
